Department of Surgery, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Interact Cardiovasc Thorac Surg. 2020 Aug 1;31(2):141-151. doi: 10.1093/icvts/ivaa094.
The benefits of preoperative intravenous (IV) iron treatment in cardiac surgery patients with preoperative anaemia or iron deficiency have not been well-established. We performed a systematic review and meta-analysis to determine the effects of treating preoperative anaemia or iron deficiency with IV iron in adult cardiac surgery patients.
We searched Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval Systems Online and Excerpta Medica Database for randomized controlled trials (RCTs) and observational studies comparing IV iron to oral iron or no iron. We performed title and abstract, full-text screening, data extraction and risk of bias assessment independently and in duplicate. We pooled data using a random effects model and evaluated the overall quality of evidence.
We identified 4 RCTs and 7 observational studies. Pooled data from observational studies suggested a benefit of IV iron compared to no iron on mortality [relative risk 0.39, 95% confidence interval (CI) 0.23-0.65; P < 0.001, very low quality], units transfused per patient (mean difference -1.22, 95% CI -1.85 to -0.60; P < 0.001, very low quality), renal injury (relative risk 0.50, 95% CI 0.36-0.69; P < 0.001, very low quality) and hospital length of stay (mean difference -4.24 days, 95% CI -6.86 to -1.63; P = 0.001, very low quality). Pooled data from RCTs demonstrated a reduction in the number of patients transfused with IV iron compared to oral or no iron (relative risk 0.81, 95% CI 0.70-0.94; P = 0.005, moderate quality). The pooled estimates of effect from RCTs for mortality, hospital length of stay, units transfused per patient and renal injury were consistent in direction with observational studies.
This meta-analysis suggests that IV iron improves postoperative morbidity in adult cardiac surgery patients with preoperative anaemia or iron deficiency. A large, rigorous, placebo-controlled, double-blinded, multicentre trial is needed to clarify the role of IV iron in this patient population.
International prospective register of systematic reviews ID Number CRD42019122844.
术前静脉(IV)铁治疗术前贫血或缺铁的心脏手术患者的益处尚未得到充分证实。我们进行了系统评价和荟萃分析,以确定在成年心脏手术患者中用 IV 铁治疗术前贫血或缺铁的效果。
我们检索了 Cochrane 对照试验中心注册库、医学文献分析和检索系统在线和文摘医学数据库,以比较 IV 铁与口服铁或无铁的随机对照试验(RCT)和观察性研究。我们独立地、重复地进行标题和摘要、全文筛选、数据提取和偏倚风险评估。我们使用随机效应模型汇总数据,并评估总体证据质量。
我们确定了 4 项 RCT 和 7 项观察性研究。来自观察性研究的汇总数据表明,与无铁相比,IV 铁在死亡率方面有获益[相对风险 0.39,95%置信区间(CI)0.23-0.65;P<0.001,极低质量]、每位患者输注的单位数(平均差异-1.22,95%CI-1.85 至-0.60;P<0.001,极低质量)、肾损伤(相对风险 0.50,95%CI 0.36-0.69;P<0.001,极低质量)和住院时间(平均差异-4.24 天,95%CI-6.86 至-1.63;P=0.001,极低质量)。来自 RCT 的汇总数据表明,与口服或无铁相比,用 IV 铁输血的患者数量减少(相对风险 0.81,95%CI 0.70-0.94;P=0.005,中等质量)。来自 RCT 的死亡率、住院时间、每位患者输注的单位数和肾损伤的汇总效应估计方向与观察性研究一致。
这项荟萃分析表明,IV 铁可改善术前贫血或缺铁的成年心脏手术患者的术后发病率。需要一项大型、严格、安慰剂对照、双盲、多中心试验来阐明 IV 铁在这一患者群体中的作用。
国际前瞻性系统评价注册库注册号 CRD42019122844。